NextCell Pharma (NXTCL) Q1 2025 earnings summary

Executive summary

• ProTrans cell therapy showed significant long-term efficacy and safety in type 1 diabetes, with improved insulin production and health outcomes in clinical studies.

• ProTrans-Young study is progressing ahead of schedule, with all age groups evaluated for safety and efficacy data for the 12-21 age group expected in April.

• Cellaviva maintained strong customer interest and plans to expand into genetic testing and preventive health services.

• QVance, launched in November, secured key partnerships and aims to become a leading analytics provider for ATMPs in the Nordics.

Financial highlights

• Operating income for Q1 2024/2025 was 2.9 MSEK, down from 4.7 MSEK year-over-year but up sequentially.

• Net sales were 2.8 MSEK, primarily from Cellaviva, compared to 4.2 MSEK in the prior year.

• Net loss after financial items improved to -8.0 MSEK from -9.8 MSEK year-over-year.

• Earnings per share were -0.11 SEK, compared to -0.28 SEK in the same quarter last year.

• Cash and cash equivalents stood at 34.1 MSEK as of November 30, 2024.

Outlook and guidance

• Focus remains on advancing ProTrans to market, with a goal to secure a partner for Phase III and commercialization by late 2026.

• Cellaviva aims to broaden its service offering and customer base in proactive healthcare.

• QVance targets growth through new partnerships and onboarding customers in the ATMP analytics market.